^
BIOMARKER:
HER-2 positive
i
Other names: ERBB2, CD340, HER-2, HER2, NEU, NGL, V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2
Entrez ID:
Related biomarkers:
›
HER-2 positive
|
HER2 Positive Breast Cancer
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
ARX788 Sensitive: C2 – Inclusion Criteria
Clin Cancer Res - 3 days (NewC2)
|
ARX788 Sensitive: C2 – Inclusion Criteria
Clin Cancer Res - 3 days - (New C3)
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
tislelizumab + ZW25 Sensitive: C3 – Early Trials
ASCO 2022 - 3 days (NewC3)
|
tislelizumab + ZW25 Sensitive: C3 – Early Trials
ASCO 2022 - 3 days - (New C3)
|
HER-2 positive
|
Gastric Cancer
|
HER-2 positive
|
Gastric Cancer
|
tislelizumab + ZW25 Sensitive: C3 – Early Trials
ASCO 2022 - 3 days (NewC3)
|
tislelizumab + ZW25 Sensitive: C3 – Early Trials
ASCO 2022 - 3 days - (New C3)
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
trastuzumab + lapatinib Sensitive: A2 - Guideline
ESMO-BC 2022 - 3 weeks (NewA2)
|
trastuzumab + lapatinib Sensitive: A2 - Guideline
ESMO-BC 2022 - 3 weeks - (New C3)
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
trastuzumab + tucatinib Sensitive: A1 - Approval
Mol Cancer Ther - 3 weeks (NewA1)
|
trastuzumab + tucatinib Sensitive: A1 - Approval
Mol Cancer Ther - 3 weeks - (New D)
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
trastuzumab + pertuzumab Sensitive: A1 - Approval
ESMO-BC 2022 - 3 weeks (NewA1)
|
trastuzumab + pertuzumab Sensitive: A1 - Approval
ESMO-BC 2022 - 3 weeks - (New B)
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval
FDA - 3 weeks (NewA1)
|
fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval
FDA - 3 weeks - (New A1)
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
HM 78136B Sensitive: C2 – Inclusion Criteria
ESMO-BC 2022 - 3 weeks (NewC2)
|
HM 78136B Sensitive: C2 – Inclusion Criteria
ESMO-BC 2022 - 3 weeks - (New C3)
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
tucatinib Sensitive: C2 – Inclusion Criteria
Mol Cancer Ther - 3 weeks (NewC2)
|
tucatinib Sensitive: C2 – Inclusion Criteria
Mol Cancer Ther - 3 weeks - (New D)
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
nivolumab + fam-trastuzumab deruxtecan-nxki Sensitive: C3 – Early Trials
ESMO-BC 2022 - 3 weeks (NewC3)
|
nivolumab + fam-trastuzumab deruxtecan-nxki Sensitive: C3 – Early Trials
ESMO-BC 2022 - 3 weeks - (New C3)
|
HER-2 positive
|
Ovarian Cancer
|
HER-2 positive
|
Ovarian Cancer
|
EDIT-202 Sensitive: D – Preclinical
ASGCT 2022 - 3 weeks (NewD)
|
EDIT-202 Sensitive: D – Preclinical
ASGCT 2022 - 3 weeks - (New D)
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
margetuximab Sensitive: A1 - Approval
|
margetuximab Sensitive: A1 - Approval
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
trastuzumab Sensitive: A1 - Approval
|
trastuzumab Sensitive: A1 - Approval
|
HER-2 positive
|
Gastric Cancer
|
HER-2 positive
|
Gastric Cancer
|
fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval
|
fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval
|
fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
ado-trastuzumab emtansine Sensitive: A1 - Approval
|
ado-trastuzumab emtansine Sensitive: A1 - Approval
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
trastuzumab Sensitive: A1 - Approval
|
trastuzumab Sensitive: A1 - Approval
|
HER-2 positive
|
Gastric Cancer
|
HER-2 positive
|
Gastric Cancer
|
pembrolizumab + trastuzumab Sensitive: A1 - Approval
|
pembrolizumab + trastuzumab Sensitive: A1 - Approval
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
pertuzumab/trastuzumab/hyaluronidase-zzxf Sensitive: A1 - Approval
|
pertuzumab / trastuzumab / hyaluronidase-zzxf Sensitive: A1 - Approval
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
Trazimera (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Trazimera (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
Ontruzant (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Ontruzant (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
Ogivri (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Ogivri (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
Kanjinti (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Kanjinti (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
Herzuma (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Herzuma (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
neratinib Sensitive: A1 - Approval
|
neratinib Sensitive: A1 - Approval
|
HER-2 positive
|
Salivary Gland Cancer
|
HER-2 positive
|
Salivary Gland Cancer
|
trastuzumab Sensitive: A1 - Approval
|
trastuzumab Sensitive: A1 - Approval
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
Zercepac (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Zercepac (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
Zercepac (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Zercepac (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 positive
|
Gastric Cancer
|
HER-2 positive
|
Gastric Cancer
|
Zercepac (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Zercepac (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
pembrolizumab + trastuzumab Sensitive: A1 - Approval
|
pembrolizumab + trastuzumab Sensitive: A1 - Approval
|
HER-2 positive
|
CRC
|
HER-2 positive
|
CRC
|
trastuzumab + pertuzumab Sensitive: A1 - Approval
|
trastuzumab + pertuzumab Sensitive: A1 - Approval
|
HER-2 positive
|
Gastric Cancer
|
HER-2 positive
|
Gastric Cancer
|
trastuzumab Sensitive: A2 - Guideline
|
trastuzumab Sensitive: A2 - Guideline
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
TCHP Sensitive: A2 - Guideline
|
TCHP Sensitive: A2 - Guideline
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
TCH Sensitive: A2 - Guideline
|
TCH Sensitive: A2 - Guideline
|
HER-2 positive
|
Gastroesophageal Cancer
|
HER-2 positive
|
Gastroesophageal Cancer
|
trastuzumab Sensitive: A2 - Guideline
|
trastuzumab Sensitive: A2 - Guideline
|
HER-2 positive
|
Esophageal Adenocarcinoma
|
HER-2 positive
|
Esophageal Adenocarcinoma
|
trastuzumab Sensitive: A2 - Guideline
|
trastuzumab Sensitive: A2 - Guideline
|
HER-2 positive
|
Endometrial Cancer
|
HER-2 positive
|
Endometrial Cancer
|
trastuzumab Sensitive: A2 - Guideline
|
trastuzumab Sensitive: A2 - Guideline
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
pertuzumab Sensitive: A2 - Guideline
|
pertuzumab Sensitive: A2 - Guideline
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
HER2 inhibitor Sensitive: A2 - Guideline
|
HER2 inhibitor Sensitive: A2 - Guideline
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
AC-TH Sensitive: A2 - Guideline
|
AC-TH Sensitive: A2 - Guideline
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
lapatinib Sensitive: A2 - Guideline
|
lapatinib Sensitive: A2 - Guideline
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
HER2 inhibitor Sensitive: A2 - Guideline
|
HER2 inhibitor Sensitive: A2 - Guideline
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
AC-THP Sensitive: A2 - Guideline
|
AC-THP Sensitive: A2 - Guideline
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
TH Sensitive: A2 - Guideline
|
TH Sensitive: A2 - Guideline
|
HER-2 positive
|
Salivary Gland Cancer
|
HER-2 positive
|
Salivary Gland Cancer
|
fam-trastuzumab deruxtecan-nxki Sensitive: A2 - Guideline
|
fam-trastuzumab deruxtecan-nxki Sensitive: A2 - Guideline
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
trastuzumab + pertuzumab Sensitive: B - Late Trials
|
trastuzumab + pertuzumab Sensitive: B - Late Trials
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
pyrotinib Sensitive: B - Late Trials
|
pyrotinib Sensitive: B - Late Trials
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
trastuzumab + pyrotinib Sensitive: B - Late Trials
|
trastuzumab + pyrotinib Sensitive: B - Late Trials
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
Trazimera (trastuzumab biosimilar) Sensitive: B - Late Trials
|
Trazimera (trastuzumab biosimilar) Sensitive: B - Late Trials
|
HER-2 positive
|
Gastric Cancer
|
HER-2 positive
|
Gastric Cancer
|
trastuzumab + pertuzumab Sensitive: B - Late Trials
|
trastuzumab + pertuzumab Sensitive: B - Late Trials
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
ado-trastuzumab emtansine + pertuzumab Sensitive: B - Late Trials
|
ado-trastuzumab emtansine + pertuzumab Sensitive: B - Late Trials
|
HER-2 positive
|
Urothelial Cancer
|
HER-2 positive
|
Urothelial Cancer
|
disitamab vedotin Sensitive: B - Late Trials
|
disitamab vedotin Sensitive: B - Late Trials
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
Ogivri (trastuzumab biosimilar) Sensitive: B - Late Trials
|
Ogivri (trastuzumab biosimilar) Sensitive: B - Late Trials
|
HER-2 positive
|
Gastric Cancer
|
HER-2 positive
|
Gastric Cancer
|
nivolumab Resistant: B - Late Trials
|
nivolumab Resistant: B - Late Trials
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
SYD985 Sensitive: B - Late Trials
|
SYD985 Sensitive: B - Late Trials
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
Ontruzant (trastuzumab biosimilar) Sensitive: B - Late Trials
|
Ontruzant (trastuzumab biosimilar) Sensitive: B - Late Trials
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
TX05 (trastuzumab biosimilar) Sensitive: B - Late Trials
|
TX05 (trastuzumab biosimilar) Sensitive: B - Late Trials
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
Kanjinti (trastuzumab biosimilar) Sensitive: B - Late Trials
|
Kanjinti (trastuzumab biosimilar) Sensitive: B - Late Trials
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
EG12014 (trastuzumab biosimilar) Sensitive: B - Late Trials
|
EG12014 (trastuzumab biosimilar) Sensitive: B - Late Trials
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
Herzuma (trastuzumab biosimilar) Sensitive: B - Late Trials
|
Herzuma (trastuzumab biosimilar) Sensitive: B - Late Trials
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
Sensitive: B - Late Trials
|
Sensitive: B - Late Trials
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
ramucirumab Sensitive: B - Late Trials
|
ramucirumab Sensitive: B - Late Trials
|
HER-2 positive
|
Gastric Cancer
|
HER-2 positive
|
Gastric Cancer
|
ramucirumab Sensitive: B - Late Trials
|
ramucirumab Sensitive: B - Late Trials
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
CYNK-101 Sensitive: B - Late Trials
|
CYNK-101 Sensitive: B - Late Trials
|
HER-2 positive
|
Gastric Cancer
|
HER-2 positive
|
Gastric Cancer
|
CYNK-101 Sensitive: B - Late Trials
|
CYNK-101 Sensitive: B - Late Trials
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
Hervelous (trastuzumab biosimilar) Sensitive: B - Late Trials
|
Hervelous (trastuzumab biosimilar) Sensitive: B - Late Trials
|
HER-2 positive
|
Small Cell Lung Cancer
|
HER-2 positive
|
Small Cell Lung Cancer
|
trastuzumab Sensitive: C1 - Off-label
|
trastuzumab Sensitive: C1 - Off-label
|
HER-2 positive
|
Endometrial Adenocarcinoma
|
HER-2 positive
|
Endometrial Adenocarcinoma
|
trastuzumab Sensitive: C1 - Off-label
|
trastuzumab Sensitive: C1 - Off-label
|
HER-2 positive
|
NSCLC
|
HER-2 positive
|
NSCLC
|
trastuzumab Sensitive: C1 - Off-label
|
trastuzumab Sensitive: C1 - Off-label
|
HER-2 positive
|
CRC
|
HER-2 positive
|
CRC
|
fam-trastuzumab deruxtecan-nxki Sensitive: C1 - Off-label
|
fam-trastuzumab deruxtecan-nxki Sensitive: C1 - Off-label
|
HER-2 positive
|
Gastroesophageal Cancer
|
HER-2 positive
|
Gastroesophageal Cancer
|
pembrolizumab + trastuzumab Sensitive: C1 - Off-label
|
pembrolizumab + trastuzumab Sensitive: C1 - Off-label
|
HER-2 positive
|
Colon Cancer
|
HER-2 positive
|
Colon Cancer
|
ado-trastuzumab emtansine Sensitive: C1 - Off-label
|
ado-trastuzumab emtansine Sensitive: C1 - Off-label
|
HER-2 positive
|
Esophageal Adenocarcinoma
|
HER-2 positive
|
Esophageal Adenocarcinoma
|
trastuzumab + pertuzumab Sensitive: C1 - Off-label
|
trastuzumab + pertuzumab Sensitive: C1 - Off-label
|
HER-2 positive
|
Solid Tumor
|
HER-2 positive
|
Solid Tumor
|
neratinib Resistant: C1 - Off-label
|
neratinib Resistant: C1 - Off-label
|
HER-2 positive
|
Gastric Cancer
|
HER-2 positive
|
Gastric Cancer
|
ado-trastuzumab emtansine Sensitive: C1 - Off-label
|
ado-trastuzumab emtansine Sensitive: C1 - Off-label
|
HER-2 positive
|
Esophageal Squamous Cell Carcinoma
|
HER-2 positive
|
Esophageal Squamous Cell Carcinoma
|
trastuzumab Sensitive: C1 - Off-label
|
trastuzumab Sensitive: C1 - Off-label
|
HER-2 positive
|
Biliary Tract Cancer
|
HER-2 positive
|
Biliary Tract Cancer
|
Herzuma (trastuzumab biosimilar) Sensitive: C1 - Off-label
|
Herzuma (trastuzumab biosimilar) Sensitive: C1 - Off-label
|
HER-2 positive
|
Biliary Tract Cancer
|
HER-2 positive
|
Biliary Tract Cancer
|
trastuzumab + pertuzumab Sensitive: C1 - Off-label
|
trastuzumab + pertuzumab Sensitive: C1 - Off-label
|
HER-2 positive
|
NSCLC
|
HER-2 positive
|
NSCLC
|
fam-trastuzumab deruxtecan-nxki Sensitive: C1 - Off-label
|
fam-trastuzumab deruxtecan-nxki Sensitive: C1 - Off-label
|
HER-2 positive
|
CRC
|
HER-2 positive
|
CRC
|
trastuzumab Sensitive: C1 - Off-label
|
trastuzumab Sensitive: C1 - Off-label
|
HER-2 positive
|
Gastric Cancer
|
HER-2 positive
|
Gastric Cancer
|
Herzuma (trastuzumab biosimilar) Sensitive: C1 - Off-label
|
Herzuma (trastuzumab biosimilar) Sensitive: C1 - Off-label
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
paclitaxel Sensitive: C2 – Inclusion Criteria
|
paclitaxel Sensitive: C2 – Inclusion Criteria
|
HER-2 positive
|
Lung Cancer
|
HER-2 positive
|
Lung Cancer
|
pyrotinib Sensitive: C2 – Inclusion Criteria
|
pyrotinib Sensitive: C2 – Inclusion Criteria
|
HER-2 positive
|
Gastric Cancer
|
HER-2 positive
|
Gastric Cancer
|
pyrotinib Sensitive: C2 – Inclusion Criteria
|
pyrotinib Sensitive: C2 – Inclusion Criteria
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
margetuximab + MGD013 Sensitive: C2 – Inclusion Criteria
|
margetuximab + MGD013 Sensitive: C2 – Inclusion Criteria
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
PRS-343 Sensitive: C2 – Inclusion Criteria
|
PRS-343 Sensitive: C2 – Inclusion Criteria
|
HER-2 positive
|
Gastric Cancer
|
HER-2 positive
|
Gastric Cancer
|
PRS-343 Sensitive: C2 – Inclusion Criteria
|
PRS-343 Sensitive: C2 – Inclusion Criteria
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
PRS-343 Sensitive: C2 – Inclusion Criteria
|
PRS-343 Sensitive: C2 – Inclusion Criteria
|
HER-2 positive
|
Gastric Cancer
|
HER-2 positive
|
Gastric Cancer
|
nivolumab + trastuzumab Sensitive: C2 – Inclusion Criteria
|
nivolumab + trastuzumab Sensitive: C2 – Inclusion Criteria
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
bevacizumab Sensitive: C2 – Inclusion Criteria
|
bevacizumab Sensitive: C2 – Inclusion Criteria
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
paclitaxel Sensitive: C2 – Inclusion Criteria
|
paclitaxel Sensitive: C2 – Inclusion Criteria
|
HER-2 positive
|
Gastric Adenocarcinoma
|
HER-2 positive
|
Gastric Adenocarcinoma
|
pembrolizumab + margetuximab Sensitive: C2 – Inclusion Criteria
|
pembrolizumab + margetuximab Sensitive: C2 – Inclusion Criteria
|
HER-2 positive
|
Solid Tumor
|
HER-2 positive
|
Solid Tumor
|
KN046 + KN026 Sensitive: C2 – Inclusion Criteria
|
KN046 + KN026 Sensitive: C2 – Inclusion Criteria
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
ado-trastuzumab emtansine + neratinib Sensitive: C2 – Inclusion Criteria
|
ado-trastuzumab emtansine + neratinib Sensitive: C2 – Inclusion Criteria
|
HER-2 positive
|
CRC
|
HER-2 positive
|
CRC
|
pyrotinib Sensitive: C2 – Inclusion Criteria
|
pyrotinib Sensitive: C2 – Inclusion Criteria
|
HER-2 positive
|
Gastric Cancer
|
HER-2 positive
|
Gastric Cancer
|
pyrotinib + SHR6390 Sensitive: C2 – Inclusion Criteria
|
pyrotinib + SHR6390 Sensitive: C2 – Inclusion Criteria
|
HER-2 positive
|
Gastroesophageal Cancer
|
HER-2 positive
|
Gastroesophageal Cancer
|
pembrolizumab Sensitive: C2 – Inclusion Criteria
|
pembrolizumab Sensitive: C2 – Inclusion Criteria
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
afatinib Sensitive: C2 – Inclusion Criteria
|
afatinib Sensitive: C2 – Inclusion Criteria
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
A166 Sensitive: C2 – Inclusion Criteria
|
A166 Sensitive: C2 – Inclusion Criteria
|
HER-2 positive
|
CRC
|
HER-2 positive
|
CRC
|
A166 Sensitive: C2 – Inclusion Criteria
|
A166 Sensitive: C2 – Inclusion Criteria
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
KN026 Sensitive: C2 – Inclusion Criteria
|
KN026 Sensitive: C2 – Inclusion Criteria
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
pembrolizumab Sensitive: C2 – Inclusion Criteria
|
pembrolizumab Sensitive: C2 – Inclusion Criteria
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
disitamab vedotin Sensitive: C2 – Inclusion Criteria
|
disitamab vedotin Sensitive: C2 – Inclusion Criteria
|
